Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This phase I/II trial studies the side effects and best dose of ruxolitinib and to see how well it works in participants with chronic myeloid leukemia with minimal residual disease while on therapy with tyrosine kinase inhibitors. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Epistemonikos ID: e25c2842605780b9a6902e7ab57b73dbcfbc8ba9
First added on: May 11, 2024